http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021120392-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff6bd2defbc0efb51598ef014a64a55d
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65586
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-665
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
filingDate 2021-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36c6a974a48c799af6c603da0a483864
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4537946a82d21df4826a07e0d05cec25
publicationDate 2021-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2021120392-A
titleOfInvention Arbosisib prodrug with high bioavailability
abstract PROBLEM TO BE SOLVED: To provide an arvocidib phosphate prodrug having higher bioavailability as compared with an arvocidib parent compound. A compound having the following structure (I) or a stereoisomer, tautomer, or a pharmaceutically acceptable salt thereof. (One of R 1 to R 3 is -P (= O) (OH) 2 , and the other two are H, respectively.) [Selection diagram] None
priorityDate 2015-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006101846-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2004529125-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466806784

Total number of triples: 35.